COMP <GO>
CRMD vs IRWD // EV/EBITDA & P/E VALUATION
CorMedix Inc. (NASDAQ) VS. Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: CRMD 7
— IRWD 3
▲ EV/EBITDA & P/E VALUATION LEADER: CRMD
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
valuation
3.0x
LAST: $3.62 (+0.28%) • MKT CAP: $598.2M
valuation
3.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRMD VS. IRWD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRMD | IRWD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 45.50% | 85.00% | -39.50 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.0x | 3.9x | -0.90 | CRMD | /valuation <GO> |
| Free Cash Flow Yield | — | 21.23% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 48.20% | 33.30% | +14.90 | CRMD | /operating-margins <GO> |
| Net Profit Margin | 52.30% | 8.10% | +44.20 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -15.70% | +195.70 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.81 | 0.20 | +1.61 | CRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.3 | 40.5 | -15.21 | IRWD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 23.2x | -19.70 | CRMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $595.5M | $598.2M | -$2.7M | IRWD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRMD REV | IRWD REV | CRMD GROSS % | IRWD GROSS % | CRMD FCF | IRWD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $311.7M | $296.2M | 88.5% | — | $172.8M | $127.0M |
| FY 2024 | $43.5M | $351.4M | 92.7% | — | -$50.7M | $103.4M |
| FY 2023 | $0 | $442.7M | — | — | -$38.4M | $183.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRMD // BETA —
IRWD // BETA —